Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which … Read more
Kalvista Pharmaceuticals Inc (KALV) - Total Assets
Latest total assets as of October 2025: $339.93 Million USD
Based on the latest financial reports, Kalvista Pharmaceuticals Inc (KALV) holds total assets worth $339.93 Million USD as of October 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kalvista Pharmaceuticals Inc - Total Assets Trend (2013–2025)
This chart illustrates how Kalvista Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Kalvista Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (April 2025)
Kalvista Pharmaceuticals Inc's total assets of $339.93 Million consist of 96.4% current assets and 3.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 39.3% |
| Accounts Receivable | $15.14 Million | 6.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Kalvista Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kalvista Pharmaceuticals Inc's current assets represent 96.4% of total assets in 2025, a decrease from 97.6% in 2013.
- Cash Position: Cash and equivalents constituted 39.3% of total assets in 2025, down from 96.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 6.0% of total assets.
Kalvista Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Kalvista Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Kalvista Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Kalvista Pharmaceuticals Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Kalvista Pharmaceuticals Inc is currently not profitable relative to its asset base.
Kalvista Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.22 | 6.87 | 9.59 |
| Quick Ratio | 7.21 | 6.87 | 9.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $280.16 Million | $ 130.10 Million | $ 55.99 Million |
Kalvista Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Kalvista Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 48.09 |
| Latest Market Cap to Assets Ratio | 1.80 |
| Asset Growth Rate (YoY) | 6.5% |
| Total Assets | $250.77 Million |
| Market Capitalization | $451.25 Million USD |
Valuation Analysis
Above Book Valuation: The market values Kalvista Pharmaceuticals Inc's assets above their book value (1.80 x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Kalvista Pharmaceuticals Inc's assets grew by 6.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Kalvista Pharmaceuticals Inc (2013–2025)
The table below shows the annual total assets of Kalvista Pharmaceuticals Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-04-30 | $250.77 Million | +6.53% |
| 2024-04-30 | $235.40 Million | +28.49% |
| 2023-04-30 | $183.20 Million | -10.14% |
| 2022-04-30 | $203.88 Million | -25.05% |
| 2021-04-30 | $272.01 Million | +193.98% |
| 2020-04-30 | $92.53 Million | -21.67% |
| 2019-04-30 | $118.13 Million | +92.43% |
| 2018-04-30 | $61.39 Million | +78.74% |
| 2017-04-30 | $34.34 Million | +38.80% |
| 2016-04-30 | $24.75 Million | -50.19% |
| 2016-03-31 | $49.67 Million | -12.53% |
| 2015-12-31 | $56.79 Million | +754.77% |
| 2015-04-30 | $6.64 Million | 0.00% |
| 2014-12-31 | $6.64 Million | -34.25% |
| 2014-04-30 | $10.11 Million | +18.48% |
| 2013-04-30 | $8.53 Million | -- |